Manufacturer:
Veloxis Pharmaceuticals
Route of Administration:
Oral
Site of Care:
Outpatient
Website:
Approved Indication:
- prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants
- prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants
Conditions:
- Solid Organ Transplant
Therapeutic Area:
- Hepatology